MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre examine To guage several intravenous doses of sifalimumab, in adult sufferers with dermatomyositis or polymyositis (NCT00533091). Most important demo aims had been to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis patients, though one of several https://russh554vgt6.targetblogs.com/profile